Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 22;10(3):423.
doi: 10.3390/jcm10030423.

Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders

Affiliations
Review

Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders

Cristiana Bianco et al. J Clin Med. .

Abstract

Anemia is a common feature of liver and bowel diseases. Although the main causes of anemia in these conditions are represented by gastrointestinal bleeding and iron deficiency, autoimmune hemolytic anemia should be considered in the differential diagnosis. Due to the epidemiological association, autoimmune hemolytic anemia should particularly be suspected in patients affected by inflammatory and autoimmune diseases, such as autoimmune or acute viral hepatitis, primary biliary cholangitis, and inflammatory bowel disease. In the presence of biochemical indices of hemolysis, the direct antiglobulin test can detect the presence of warm or cold reacting antibodies, allowing for a prompt treatment. Drug-induced, immune-mediated hemolytic anemia should be ruled out. On the other hand, the choice of treatment should consider possible adverse events related to the underlying conditions. Given the adverse impact of anemia on clinical outcomes, maintaining a high clinical suspicion to reach a prompt diagnosis is the key to establishing an adequate treatment.

Keywords: autoimmune disease; autoimmune hemolytic anemia; autoimmune hepatitis; chronic liver disease; diagnosis; inflammatory bowel disease; primary biliary cholangitis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Maruyama S., Hirayama C., Yamamoto S., Koda M., Udagawa A., Kadowaki Y., Inoue M., Sagayama A., Umeki K. Red blood cell status in alcoholic and non-alcoholic liver disease. J. Lab. Clin. Med. 2001;138:332–337. doi: 10.1067/mlc.2001.119106. - DOI - PubMed
    1. Qamar A.A., Grace N.D., Groszmann R.J., Garcia–Tsao G., Bosch J., Burroughs A.K., Ripoll C., Maurer R., Planas R., Escorsell A., et al. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. Clin. Gastroenterol. Hepatol. 2009;7:689–695. doi: 10.1016/j.cgh.2009.02.021. - DOI - PMC - PubMed
    1. Scheiner B., Semmler G., Maurer F., Schwabl P., Bucsics T.A., Paternostro R., Bauer D., Simbrunner B., Trauner M., Mandorfer M., et al. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver Int. 2020;40:194–204. doi: 10.1111/liv.14229. - DOI - PMC - PubMed
    1. Bothou C., Rüschenbaum S., Kubesch A., Quenstedt L., Schwarzkopf K., Welsch C., Zeuzem S., Welzel T.M., Lange C.M. Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis. J. Clin. Med. 2020;9:1263. doi: 10.3390/jcm9051263. - DOI - PMC - PubMed
    1. Piano S., Tonon M., Vettore E., Stanco M., Pilutti C., Romano A., Mareso S., Gambino C., Brocca A., Sticca A., et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J. Hepatol. 2017;67:1177–1184. doi: 10.1016/j.jhep.2017.07.008. - DOI - PubMed